- Fusion Pharmaceuticals ( NASDAQ: FUSN ) said on Monday the first patient had been dosed in the Phase 1/2 study testing FPI-1966 in patients with advanced solid tumors.
- The study will evaluate FPI-1966 in patients with solid tumors expressing FGFR3, a validated cancer target found in multiple tumor types, notably bladder, ovarian and head and neck cancers.
- The study will employ a 3 + 3 dose escalation design to evaluate multiple ascending doses of FPI-1966.
For further details see:
Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment